MitoBurn from NNB Nutrition now self-affirmed GRAS
NNB Nutrition’s MitoBurn, a non-protein amino acid metabolite of the branched-chain amino acid L-valine, is now self-affirmed GRAS as a powdered food ingredient in sports drinks and in grain-based bars, nutrition bars, and instant-powdered nutritional beverages.
Photo © iStockphoto.com
NNB Nutrition’s MitoBurn (β-aminoisobutyric Acid, or L-Baiba), a non-protein amino acid metabolite of the branched-chain amino acid L-valine, is now self-affirmed GRAS (generally recognized as safe) as a powdered food ingredient in sports drinks and in grain-based bars, nutrition bars, and instant-powdered nutritional beverages.
L-Baiba is generated both in the body and naturally in plants such as theobroma cacao and fabaceae. In humans, it’s produced by skeletal muscle during exercise, playing a role in the benefits of regular exercise, including healthy glucose uptake, increased free fatty acid oxidation, reduced fat mass, and mitochondrial health. According to Shawn Wells, CSO of NNB Nutrition, L-Baiba is also associated with the browning of white adipose tissues, in which the oxidation of fatty acids allows more fat to be converted to ketones as fuel for exercise.
“With our GRAS certification, we believe this powerful cutting-edge ingredient will be a huge hit in the dietary supplement industry,” Kylin Liao, the founder of NNB Nutrition, said in a press release.
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
